Lou Panaccio - 04 Jun 2025 Form 4 Insider Report for AVITA Medical, Inc. (RCEL)

Role: Director
Signature: /s/ Nicole Kelsey, by power of attorney
Issuer symbol: RCEL
Transactions as of: 04 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 05 Jun 2025, 16:35:39 UTC
Previous filing: 06 Jun 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Panaccio Lou	Director	C/O AVITA MEDICAL 28159 AVENUE STANFORD, SUITE 220, VALENCIA	/s/ Nicole Kelsey, by power of attorney	05 Jun 2025	0001816237

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RCEL	Common Stock	Award		+10,022	+22%		56,428	21 Jan 2025	Direct	F1, F2, F3
holding	RCEL	Common Stock						5,972	04 Jun 2025	See footnote	F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RCEL	Stock Options (Right to Buy)	Award	$0	+4,295		$0.000000	4,295	21 Jan 2025	Common Stock	4,295	$8.73	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 21, 2025. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.
F2	Includes unvested RSUs.
F3	Includes 70,460 of the Issuer's CDIs. The Reporting Person holds 70,460 CDIs, which translate into 14,092 of the shares of Common Stock set forth above.
F4	Reflects 29,860 CDIs, which translate into the 5,972 shares of Common Stock set forth above.
F5	These CDIs are held by The Panaccio Superannuation Fund (the "Fund"). The Reporting Person is a director of Tercus Pty Ltd, trustee of the Fund, and is a beneficiary of the Fund. The Reporting Person may be deemed to have shared voting and dispositive power over the CDIs held by the Fund but disclaims such beneficial ownership, except to the extent of his pecuniary interest therein.
F6	On January 6, 2025, the Board of Directors approved a grant of 4,295 options to acquire 4,295 shares of Common Stock to each of its non-executive directors, with a grant date of January 21, 2025 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $8.73. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.